

Erich Bluhmki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4237544/publications.pdf>

Version: 2024-02-01

17
papers

11,964
citations

759055

12
h-index

887953

17
g-index

17
all docs

17
docs citations

17
times ranked

9004
citing authors

#	ARTICLE	IF	CITATIONS
1	Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. <i>New England Journal of Medicine</i> , 2008, 359, 1317-1329.	13.9	5,749
2	Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). <i>Lancet, The</i> , 1998, 352, 1245-1251.	6.3	3,216
3	Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. <i>Lancet, The</i> , 2014, 384, 1929-1935.	6.3	1,971
4	Stroke treatment with alteplase given 3-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. <i>Lancet Neurology, The</i> , 2009, 8, 1095-1102.	4.9	303
5	Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes. <i>Stroke</i> , 2016, 47, 2373-2379.	1.0	193
6	Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. <i>Lancet Neurology, The</i> , 2016, 15, 925-933.	4.9	187
7	Influence of Age on Outcome From Thrombolysis in Acute Stroke. <i>Stroke</i> , 2010, 41, 2840-2848.	1.0	97
8	European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: EXTEND. <i>International Journal of Stroke</i> , 2016, 11, 260-267.	2.9	69
9	Towards a Digital Bioprocess Replica: Computational Approaches in Biopharmaceutical Development and Manufacturing. <i>Trends in Biotechnology</i> , 2020, 38, 1141-1153.	4.9	64
10	Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials. <i>International Journal of Stroke</i> , 2018, 13, 175-189.	2.9	36
11	Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years. <i>Stroke</i> , 2020, 51, 2322-2331.	1.0	33
12	Artificial neural networks for the prediction of solvation energies based on experimental and computational data. <i>Physical Chemistry Chemical Physics</i> , 2020, 22, 24359-24364.	1.3	15
13	Generic and specific recurrent neural network models: Applications for large and small scale biopharmaceutical upstream processes. <i>Biotechnology Reports (Amsterdam, Netherlands)</i> , 2021, 31, e00640.	2.1	12
14	Validation Is Not Verification: Precise Terminology and Scientific Methods in Bioprocess Modeling. <i>Trends in Biotechnology</i> , 2021, 39, 1117-1119.	4.9	8
15	The SITS-UTMOST: A registry-based prospective study in Europe investigating the impact of regulatory approval of intravenous Actilyse in the extended time window (3-4.5h) in acute ischaemic stroke. <i>European Stroke Journal</i> , 2016, 1, 213-221.	2.7	7
16	Holistic Process Models: A Bayesian Predictive Ensemble Method for Single and Coupled Unit Operation Models. <i>Processes</i> , 2022, 10, 662.	1.3	3
17	Online Tool to Improve Stratification of Adverse Events in Stroke Clinical Trials. <i>Stroke</i> , 2016, 47, 882-885.	1.0	1